Polyspecific Antibodies in Lymphoproliferative T-cell Disorders

This trial is testing a new type of immune therapy (polyspecific antibodies) that targets multiple proteins at once in people with rare and aggressive T-cell lymphomas (cancers of the immune system's T-cells) that have come back or stopped responding to treatment. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of a relapsed or refractory T-cell lymphoma (such as hepatosplenic T-cell lymphoma, anaplastic large cell lymphoma, or nodal TFH lymphoma, among others, per WHO 2022 classification) - Your cancer has returned after prior treatments **You may NOT be eligible if...** - You have active brain involvement of your lymphoma - You have severe organ dysfunction or serious active infections - You are pregnant or breastfeeding - You have recently received other investigational therapies Talk to your doctor to see if this trial is right for you.